Revolutionizing Antibody Drug Conjugates With Precision and Innovation

Breakthrough
Linker Technology

Baylink's novel linkers expand payload diversity, enabling use of hydrophobic drugs.

Unique design features are incorporated in the linker technology to reduce  off-target effects and improve payload delivery to tumors.

Innovative
Payloads

Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.

Protein degrader ADCs using molecular glues and PROTAC payloads offer new therapeutic approaches and are under development 

at Baylink.

Addressing
Key Challenges

Baylink tackles critical issues: improving therapeutic index, expanding payload diversity, and overcoming resistance. 

​

This drives the next wave 

of precision ADCs.